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ABSTRACT 
Ethambutol is one of the first line drugs for treating tuberculosis. Its toxic effects on the optic nerve 
are majorly classified as reversible. However, worsening of vision and permanent vision loss after 
ethambutol discontinuation is also documented. To determine the effect of ethambutol toxicity on 
oligodendrocytes at different periods of treatment. Twenty-five male adult wistar rats of 110-130g 
average weight were housed in cages, exposed to 12-hour of dark and light cycles. After one week 
of acclimatization, five animals were randomly selected and sacrificed prior to ethambutol treatment 
for the control group (week 0). The remaining 20 animals were each orally administered 
100mg/kg/day ethambutol. Five animals were randomly picked and sacrificed at the end of first, 
second, third, and fourth week of ethambutol treatment. There was no statistically significant 
difference in the number of oligodendrocyte cells obtained at the different stages of ethambutol 
treatment. Oligodendrocytes are not vulnerable to ethambutol toxicity for at least one month and 
they play a key role in reversing ethambutol induced neuropathy through myelin sheaths 
reconstruction.   
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INTRODUCTION 
Ethambutol (EMB) also known as Myambutol, 
is one of the drugs for treating tuberculosis 
(TB) (Somasundaram et al., 2014). Worldwide, 
one‐third of the population is affected by 
tuberculosis (The Lancet Infectious Diseases, 
2011). The development of multidrug resistant 
TB along with Human Immunodeficiency 
Virus/Acquired Immunodeficiency Syndrome 
condition have greatly increased the incidence 
of TB, making it a primary public health threat 
(Gray and Cohn, 2013). Ethambutol is the only 
effective first line anti-tuberculosis agent that 
prevents development of resistance to 
companion drugs and broadening of the 
resistance spectrum (Orikiriza et al., 2015). 
Soon after its discovery in 1960s (Forbes et al., 
1962), EMB was reported to cause changes in 
the optic nerve structure that result into optic 
neuropathy. Damage to the optic nerve 
structure is one of the most serious conditions 
because of the inability of the fibres to 
regenerate (Tawse et al., 2014), posing a risk 
of permanent and potentially severe loss of 
vision (Boulanger et al., 2013). Optic nerve 
consists of the myelinated axons of the retinal 
ganglion cells (de Lima et al., 2012), these 
mediate for the special sense of vision via the 
Special somatic afferent fibre (Watson, 2014). 
Oligodendrocytes, the major neuroglia in the 
optic nerve are responsible for production of 
myelin sheaths of the nerve fibres (Simons and 
Nave, 2016), which facilitates the rapid 
conduction of axons(Chamberlain et al., 2016) 
. 
Ethambutol induced toxic optic neuropathy is a 
symmetrical progressive painless condition, 
presenting with symptoms such as; blurring of 
vision, decrease in visual acuity (Rasool et al., 
2015), bitemporal visual field scotoma defects, 
centro-caecal scotoma and disturbances in 
colour perception (Han et al., 2015). Different 
experimental animal studies using toxic doses 
of EMB have reported vacuolations, axonal 
fragmentation, inflammatory changes, 
demyelination and central necrosis in the optic 
nerve (Osaguona et al., 2014;Yang et al., 
2016). 
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Although EMB toxicity is classically described as 
reversible on discontinuation with complete 
recovery over period of weeks to months (Holla 
et al., 2015), worsening of vision after EMB 
discontinuation has been observed in some 
patients (Garg et al., 2015). Previous studies 
have reported severe, and irreversible vision 
loss despite frequent monitoring and standard 
dosages (Chen, Lin, and Sheu, 2015). 
Moreover, apart from stopping the use of EMB, 
there is no specific treatment available for 
alleviating EMB induced toxic optic neuropathy 
(Rasool et al., 2015). This study aimed at 
exploring the role of oligodendrocytes in 
reversing this condition by determining the 
effect of ethambutol toxicity on 
oligodendrocytes at different periods of 
treatment. 
 
MATERIALS AND METHODS 
Ethical clearance for this study was given by 
the Directorate of Postgraduate Studies and 
Research of Kampala International University, 
Uganda. All experimental procedures on the 
animal were conducted in accordance with the 
2010 National Research Council Guide for Care 
and use of Laboratory Animals. 
A total of 25 male adult wistar rats of 110-130g 
average weight were used in this study. The 
animals were housed in cages, exposed to 12-
hour of dark and light cycles. They were fed on 
pellets and provided with tap water ad libitum. 
Treatment with ethambutol started after one 
week of acclimatization. Administration of 
ethambutol was performed as previously 
described (Elna et al., 2018), and doses of 
100mg/kg/day were used to induce visual 
impairment in the experimental animals. Five 
animals were randomly selected and sacrificed 
prior to ethambutol treatment for the control 
group (week 0). Five animals were randomly 
picked and sacrificed at the end of 1, 2, 3, 4 
weeks of ethambutol treatment. 
 
Obtaining the optic nerves and tissue 
processing were performed as previously 
described (Owembabazi et al., 2017) Sections 
of 5μm thickness were cut using an ultra-
microtome, and mounted on salinized glass 
slides. These were heat fixed, put in xylene for 
3 minutes to remove paraffin wax and then put 
in two containers of absolute alcohol for 30 
seconds each to remove the xylene. They were 
then transferred to 90% alcohol for 30 seconds 
and to 70% alcohol for 30 seconds and rinsed 
in distilled water. The clean slides were then 
put in toluidine blue stain for 2 minutes, after 
which they were washed thoroughly in tap 
water. They were then dehydrated through 
95% and 100% alcohols, then cleared in 
xylene and a coverslip was immediately put 
(Ephros, 2004). The slides were examined 
under a light microscope, the number of 
oligodendrocytes were counted per unit area of 
0.50 mm2, after calibrating the ocular 
micrometre with stage linear micrometre, using 
X40 objective. 
 
Using graph pad prisms V6, mean ± SEM were 
obtained and analysis of variance (ANOVA) was 
applied to determine group mean differences 
in the number of oligodendrocytes between the 
control and test groups. A post-HOC Tuckey 
test was used to determine which means 




Stained cross sections of the optic nerves were 
observed under light microscope, the 
oligodendrocytes were identified as small cells 
with a central dark nucleus and a rim of 
unstained cytoplasm. The average number of 
oligodendrocytes cells at the different stages of 
ethambutol treatment were; week 1: 
22.4±2.4, week 2: 22.4±2.34, week 3: 
23.4±1.03, and week 4: 21±1.98. When these 
were each compared to 23±1.41 that was 
obtained in the animals that were not treated 
with ethambutol (week 0), the differences 
were all statistically insignificant (p > 0.05). 







Figure 1: Photomicrographs of Optic Nerve Cross Section, arrow pointing at oligodendrocyte cell (OLG). Toluidine blue 
stain Stain, X40. 
 



















































Figure 2: A line graph showing the number of oligodendrocyte cells at different periods o the experiment. The p values 
comparison against the negative control (Week 0); Week 1=0.9980, Week 2=0.9980, Week 3 = 0.9997, Week 4 = 0.8701.  
 






In this study, we investigated the effect of 
ethambutol toxicity on oligodendrocytes to 
explore their role in reversing ethambutol 
induced toxic optic neuropathy. Our results 
(figure 1) showed no significant differences in 
all preparations after different periods of 
treatment. This is consistent with earlier 
findings; reporting no significant changes in 
the number of oligodendrocytes after a month 
of ethambutol treatment in experimental 
animals (Kinoshita et al., 2012). However, a 
recent study reported optic nerve 
oligodendropenia in rabbits after 6 weeks of 
administering 100mg/kg/day of ethambutol 
(Zada and Badar, 2018). 
Oligodendrocytes deposit myelin around the 
axons (Simons and Nave, 2016). This enables 
fast transmission of signals through the nerves 
in central nervous system (Chamberlain et al., 
2016). Ethambutol toxicity damages myelin, 
causing progressive axonal loss that results 
into ethambutol induced optic neuropathy 
(Talbert and Sadun, 2010). Visual impairment 
has also been reported in some neurological 
disorders such as; multiple sclerosis that cause 
extensive demyelination (Balcer et al., 2015). 
Based on our finding, oligodendrocytes are not 
vulnerable to ethambutol toxicity for at least 
one month. Therefore, they are able to 
reconstruct the myelin sheaths around the 
optic nerve axons after ethambutol 
discontinuation and thus take part in reversing 
ethambutol induced neuropathy. 
 
In conclusion, the number and integrity of 
oligodendrocytes are both vital in the process 
of reversing ethambutol induced optic 
neuropathology. We stipulate that patients 
who develop severe, irreversible vision loss 
despite EMB discontinuation, most likely had 
existing oligodendrocyte cell disorders. 
We recommend that patients with 
demyelinating diseases that are undergoing 
ethambutol treatment are put under visual 
impairment monitoring.  Further studies should 
determine the neuroglia genetic variations in 
the patients that develop irreversible 
ethambutol induced optic neuropathy.   
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